Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthonius de Boer

Showing results (241-250 of 282) with videos related to

Pageof 29
Sort By:
The Annals of Pharmacotherapy|March 20, 2002
Discrepancies between medical and pharmacy records for patients on anti-HIV drugsMonique M R de Maat, Suzanne V Frankfort, Ron A A Mathôt, et al.
Pharmacogenomics|October 11, 2014
No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarctionMaarten Leusink, Catherine E de Keyser, N Charlotte Onland-Moret, et al.
Pharmacogenetics and Genomics|January 10, 2012
The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stentingAnkie M Harmsze, Jochem W van Werkum, Christian M Hackeng, et al.
Pharmacogenetics|May 7, 2004
Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in menAnke Hilse Maitland-van der Zee, Olaf H Klungel, Bruno H Ch Stricker, et al.
European Heart Journal|June 4, 2011
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic dataRianne M F van Schie, Judith A M Wessels, Saskia le Cessie, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 29, 2020
Association of beta-blockers and first-registered heart rhythm in out-of-hospital cardiac arrest: real-world data from population-based cohorts across two European countriesCarlo A Barcella, Talip E Eroglu, Michiel Hulleman, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 11, 2019
Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countriesTalip E Eroglu, Grimur H Mohr, Marieke T Blom, et al.
Drug Metabolism and Drug Interactions|October 26, 2012
Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance doseRianne M F van Schie, Talitha I Verhoef, Saskia B Boejharat, et al.
Pharmacogenomics|September 13, 2018
Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patientsHedy Maagdenberg, Marc B Bierings, C Heleen van Ommen, et al.
Breast Cancer Research : BCR|August 6, 2015
Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidenceHeleen K Bronsveld, Bas ter Braak, Øystein Karlstad, et al.
Pageof 29

Showing results (241-250 of 282) with videos related to

Sort By:
Pageof 29
The Annals of Pharmacotherapy|March 20, 2002
Discrepancies between medical and pharmacy records for patients on anti-HIV drugsMonique M R de Maat, Suzanne V Frankfort, Ron A A Mathôt, et al.
Pharmacogenomics|October 11, 2014
No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarctionMaarten Leusink, Catherine E de Keyser, N Charlotte Onland-Moret, et al.
Pharmacogenetics and Genomics|January 10, 2012
The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stentingAnkie M Harmsze, Jochem W van Werkum, Christian M Hackeng, et al.
Pharmacogenetics|May 7, 2004
Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in menAnke Hilse Maitland-van der Zee, Olaf H Klungel, Bruno H Ch Stricker, et al.
European Heart Journal|June 4, 2011
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic dataRianne M F van Schie, Judith A M Wessels, Saskia le Cessie, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 29, 2020
Association of beta-blockers and first-registered heart rhythm in out-of-hospital cardiac arrest: real-world data from population-based cohorts across two European countriesCarlo A Barcella, Talip E Eroglu, Michiel Hulleman, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 11, 2019
Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countriesTalip E Eroglu, Grimur H Mohr, Marieke T Blom, et al.
Drug Metabolism and Drug Interactions|October 26, 2012
Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance doseRianne M F van Schie, Talitha I Verhoef, Saskia B Boejharat, et al.
Pharmacogenomics|September 13, 2018
Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patientsHedy Maagdenberg, Marc B Bierings, C Heleen van Ommen, et al.
Breast Cancer Research : BCR|August 6, 2015
Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidenceHeleen K Bronsveld, Bas ter Braak, Øystein Karlstad, et al.
Pageof 29